Skip to main content
PMC home page
British Medical Journal (Clinical Research Ed.) logoLink to British Medical Journal (Clinical Research Ed.)
. 1983 Feb 19;286(6365):587–590. doi: 10.1136/bmj.286.6365.587

Drug treatment of primary hyperparathyroidism: use of clodronate disodium.

D L Douglas, J A Kanis, A D Paterson, D J Beard, E C Cameron, M E Watson, S Woodhead, J Williams, R G Russell
PMCID: PMC1546876  PMID: 6218861

Abstract

Clodronate disodium (dichloromethylene diphosphonate), a specific inhibitor of bone resorption, was given by mouth (1.0-3.2 g daily) to nine patients with primary hyperparathyroidism for two to 32 weeks so that its clinical and metabolic effects could be evaluated. Bone resorption decreased in all patients as judged by a fall in the fasting urinary calcium to creatinine and hydroxyproline to creatinine ratios. Serum calcium concentration was increased in all patients before treatment and fell in response to treatment to values near the upper end of the normal range. Hypercalcaemia and hypercalciuria recurred when treatment was stopped. In three patients treated for longer than 19 weeks clodronate failed to sustain the reduction in serum calcium concentration but the concentration remained below pretreatment values. These results suggest that clodronate may be of use in the medical management of primary hyperparathyroidism, particularly in patients in whom suppression of bone disease is desirable before surgery or in whom surgery is contraindicated.

Full text

PDF
587

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Addison G. M., Hales C. N., Woodhead J. S., O'Riordan J. L. Immunoradiometric assay of parathyroid hormone. J Endocrinol. 1971 Mar;49(3):521–530. doi: 10.1677/joe.0.0490521. [DOI] [PubMed] [Google Scholar]
  2. Bijvoet O. L., Morgan D. B., Fourman P. The assessment of phosphate reabsorption. Clin Chim Acta. 1969 Oct;26(1):15–24. doi: 10.1016/0009-8981(69)90280-0. [DOI] [PubMed] [Google Scholar]
  3. Chapuy M. C., Meunier P. J., Alexandre C. M., Vignon E. P. Effects of disodium dichloromethylene diphosphonate on hypercalcemia produced by bone metastases. J Clin Invest. 1980 May;65(5):1243–1247. doi: 10.1172/JCI109780. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Coe F. L., Favus M. J. Does mild, asymptomatic hyperparathyroidism require surgery? N Engl J Med. 1980 Jan 24;302(4):224–225. doi: 10.1056/NEJM198001243020408. [DOI] [PubMed] [Google Scholar]
  5. Douglas D. L., Duckworth T., Kanis J. A., Preston C., Beard D. J., Smith T. W., Underwood I., Woodhead J. S., Russell R. G. Biochemical and clinical responses to dichloromethylene diphosphonate (Cl2MDP) in Paget's disease of bone. Arthritis Rheum. 1980 Oct;23(10):1185–1192. doi: 10.1002/art.1780231017. [DOI] [PubMed] [Google Scholar]
  6. Douglas D. L., Duckworth T., Russell R. G., Kanis J. A., Preston C. J., Preston F. E., Prenton M. A., Woodhead J. S. Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease. Lancet. 1980 May 17;1(8177):1043–1047. doi: 10.1016/s0140-6736(80)91496-8. [DOI] [PubMed] [Google Scholar]
  7. Frijlink W. B., Bijvoet O. L., te Velde J., Heynen G. Treatment of Paget's disease with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.). Lancet. 1979 Apr 14;1(8120):799–803. doi: 10.1016/s0140-6736(79)91318-7. [DOI] [PubMed] [Google Scholar]
  8. Harris W. H., Heaney R. P. Skeletal renewal and metabolic bone disease. N Engl J Med. 1969 Feb 6;280(6):303–concl. doi: 10.1056/NEJM196902062800605. [DOI] [PubMed] [Google Scholar]
  9. Kaplan R. A., Geho W. B., Poindexter C., Haussler M., Dietz G. W., Pak C. Y. Metabolic effects of diphosphonate in primary hyperparathyroidism. J Clin Pharmacol. 1977 Jul;17(7):410–419. doi: 10.1002/j.1552-4604.1977.tb04624.x. [DOI] [PubMed] [Google Scholar]
  10. Meunier P. J., Chapuy M. C., Alexandre C., Bressot C., Edouard C., Vignon C., Mathieu L., Trechsel U. Effects of disodium dichloromethylene diphosphonate on Paget's disease of bone. Lancet. 1979 Sep 8;2(8141):489–492. doi: 10.1016/s0140-6736(79)91551-4. [DOI] [PubMed] [Google Scholar]
  11. Palmer F. J., Sawyers T. M., Wierzbinski S. J. Cimetidine and hyperparathyroidism. N Engl J Med. 1980 Mar 20;302(12):692–692. doi: 10.1056/NEJM198003203021216. [DOI] [PubMed] [Google Scholar]
  12. Shane E., Baquiran D. C., Bilezikian J. P. Effects of dichloromethylene diphosphonate on serum and urinary calcium in primary hyperparathyroidism. Ann Intern Med. 1981 Jul;95(1):23–27. doi: 10.7326/0003-4819-95-1-23. [DOI] [PubMed] [Google Scholar]
  13. Sherwood J. K., Ackroyd F. W., Garcia M. Effect of cimetidine on circulating parathyroid hormone in primary hyperparathyroidism. Lancet. 1980 Mar 22;1(8169):616–620. doi: 10.1016/s0140-6736(80)91117-4. [DOI] [PubMed] [Google Scholar]
  14. Siris E. S., Sherman W. H., Baquiran D. C., Schlatterer J. P., Osserman E. F., Canfield R. E. Effects of dichloromethylene diphosphonate on skeletal mobilization of calcium in multiple myeloma. N Engl J Med. 1980 Feb 7;302(6):310–315. doi: 10.1056/NEJM198002073020602. [DOI] [PubMed] [Google Scholar]
  15. van Breukelen F. J., Bijvoet O. L., van Oosterom A. T. Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.). Lancet. 1979 Apr 14;1(8120):803–805. doi: 10.1016/s0140-6736(79)91319-9. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal (Clinical research ed.) are provided here courtesy of BMJ Publishing Group

RESOURCES